Gastrointestinal Manifestations and Treatment Options in Fabry Disease Patients. A Systematic Review.


Journal

Journal of gastrointestinal and liver diseases : JGLD
ISSN: 1842-1121
Titre abrégé: J Gastrointestin Liver Dis
Pays: Romania
ID NLM: 101272825

Informations de publication

Date de publication:
19 03 2022
Historique:
received: 24 06 2021
accepted: 27 01 2022
entrez: 20 3 2022
pubmed: 21 3 2022
medline: 28 4 2022
Statut: epublish

Résumé

Fabry disease (FD) is a rare chronic genetic disorder that presents under a paucity of symptoms. Gastrointestinal (GI) involvement is a common event and can sometimes be debilitating, but relatively often it is overlooked. We aimed to provide a systematic review of main GI symptoms in FD patients and treatment possibilities. We completed a systematic review of literature, using the MeSH terms: "Fabry disease", "gastrointestinal", "gastrointestinal", "digestive", "manifestations", "symptoms", "clinical", "treatment", "therapy" and the supplementary concepts "enzyme replacement", "chaperone", "Migalastat", in different combinations, with defined inclusion and exclusion criteria. From 221 initial studies identified, through our selection process we included a final date base of 51 articles on GI signs and symptoms and their treatment. The primary GI manifestations of the disease consist of abdominal pain, bowel movement disorders or nausea and vomiting. Less frequent manifestations such as diverticular bowel disease, gastroesophageal reflux or achalasia have also been described. Main treatment options in FD are represented by enzyme replacement therapy and chaperone treatment. Patients presenting with GI symptoms unfortunately do not always respond to enzyme replacement, necessitating symptomatic relief. Fabry disease is a rare disease that often involves the GI tract, affecting patients' quality of life and burdening the healthcare system. Physicians must be aware of the multitude of manifestations in this category of patients, to promptly recognize and treat them.

Sections du résumé

BACKGROUND AND AIMS
Fabry disease (FD) is a rare chronic genetic disorder that presents under a paucity of symptoms. Gastrointestinal (GI) involvement is a common event and can sometimes be debilitating, but relatively often it is overlooked. We aimed to provide a systematic review of main GI symptoms in FD patients and treatment possibilities.
METHODS
We completed a systematic review of literature, using the MeSH terms: "Fabry disease", "gastrointestinal", "gastrointestinal", "digestive", "manifestations", "symptoms", "clinical", "treatment", "therapy" and the supplementary concepts "enzyme replacement", "chaperone", "Migalastat", in different combinations, with defined inclusion and exclusion criteria.
RESULTS
From 221 initial studies identified, through our selection process we included a final date base of 51 articles on GI signs and symptoms and their treatment. The primary GI manifestations of the disease consist of abdominal pain, bowel movement disorders or nausea and vomiting. Less frequent manifestations such as diverticular bowel disease, gastroesophageal reflux or achalasia have also been described. Main treatment options in FD are represented by enzyme replacement therapy and chaperone treatment. Patients presenting with GI symptoms unfortunately do not always respond to enzyme replacement, necessitating symptomatic relief.
CONCLUSION
Fabry disease is a rare disease that often involves the GI tract, affecting patients' quality of life and burdening the healthcare system. Physicians must be aware of the multitude of manifestations in this category of patients, to promptly recognize and treat them.

Identifiants

pubmed: 35306547
doi: 10.15403/jgld-3855
doi:

Types de publication

Journal Article Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

98-106

Auteurs

Dan Radulescu (D)

University of Medicine and Pharmacy, Faculty of Medicine, Cluj-Napoca; Clinical Municipal Hospital, Cluj-Napoca, Romania.

Dana Crisan (D)

University of Medicine and Pharmacy, Faculty of Medicine, Cluj-Napoca; Clinical Municipal Hospital, Cluj-Napoca, Romania.

Valentin Militaru (V)

University of Medicine and Pharmacy, Faculty of Medicine, Cluj-Napoca; Clinical Municipal Hospital, Cluj-Napoca, Romania.

Elena Buzdugan (E)

University of Medicine and Pharmacy, Faculty of Medicine, Cluj-Napoca; Clinical Municipal Hospital, Cluj-Napoca, Romania.

Laurentiu Stoicescu (L)

University of Medicine and Pharmacy, Faculty of Medicine, Cluj-Napoca; Clinical Municipal Hospital, Cluj-Napoca, Romania.

Alin Grosu (A)

University of Medicine and Pharmacy, Faculty of Medicine, Cluj-Napoca; Clinical Municipal Hospital, Cluj-Napoca, Romania.

Cristina Vlad (C)

University of Medicine and Pharmacy, Faculty of Medicine, Cluj-Napoca; Clinical Rehabilitation Hospital, Cluj-Napoca, Romania.

Cristiana Grapa (C)

University of Medicine and Pharmacy, Faculty of Medicine, Cluj-Napoca, Romania. cristianagrapa@yahoo.com.

Maria L Radulescu (ML)

University of Medicine and Pharmacy, Faculty of Medicine, Cluj-Napoca; Clinical Municipal Hospital, Cluj-Napoca, Romania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH